RE:Mgmt Compensation while still in development phaseJust for clarity, most of Deschamps' 2017 compensation comprised options granted (at an exercise price of C$10.80 i.e. they are currently under water). This non-cash compensation is typical and acceptable for start-ups.
| Name and Principal Position | Period | Salary$ | Option Awards ($) | Non-Equity Incentive Plan Compensation ($) | All Other Compensation ($) (8) | Total ($) |
| Philippe Deschamps Chief Executive Officer | Fiscal year ended December 31, 2017 | 411,333 | 1,168,031(2) | 99,840 | 17,956 | 1,697,160 |
| Twelve months ended December 31, 2016(1) | 400,000 | 748,625(3) | 90,000 | 15,000 | 1,253,625 |
| Fiscal year ended March 31, 2016 | 400,000 | -- | 72,000 | 15,000 | 487,000 |
| | Fiscal year ended March 31, 2015 | 360,417 | 432,198 (4) | 120,000 | 5,000 | 917,615 |
steelinvestor wrote: I am not pleased that given the development time, battered share price etc that the CEO is taking compensation well ABOVE industry average and for a company at this stage of comercialization. Not cool imho.... As per Simply Wall St.; CEO
Phil Deschamps | COMPENSATION | $1,697,160 |
| AGE | 56 |
| TENURE AS CEO | 4.8 years |
CEO BIO
CEO COMPENSATION
Total CompensationSalaryHelius Medical Technologies's Earnings2015201620172018$0M$3MSalary: $300,000.00 - Phil's compensation has increased whilst company is loss making.
- Phil's remuneration is higher than average for companies of similar size in Canada.
Read more at https://stockhouse.com/companies/bullboard?symbol=t.div&postid=29458125#AgpxgRMKxgLAtpSQ.99